PMN RSI Chart
Last 7 days
-2.1%
Last 30 days
-0.5%
Last 90 days
-6.6%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 23, 2023 | farfel gail m | acquired | - | - | 53,192 | chief executive officer |
Aug 23, 2023 | milbury max a. | acquired | - | - | 13,297 | principal accounting officer |
Aug 23, 2023 | malenfant gavin t. | acquired | - | - | 2,660 | chief operating officer |
Aug 23, 2023 | kirwin patrick d. | acquired | - | - | 11,000 | - |
Aug 23, 2023 | cashman neil | acquired | - | - | 10,643 | chief scientific officer |
Dec 16, 2022 | williams eugene | bought | 9,290 | 4.645 | 2,000 | - |
Dec 15, 2022 | kirwin patrick d. | bought | 9,020 | 4.51 | 2,000 | - |
Dec 14, 2022 | farfel gail m | bought | 4,940 | 4.94 | 1,000 | chief executive officer |
Dec 13, 2022 | kirwin patrick d. | bought | 4,870 | 4.87 | 1,000 | - |
Dec 12, 2022 | williams eugene | bought | 5,075 | 5.075 | 1,000 | - |
Which funds bought or sold PMN recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | BANK OF AMERICA CORP /DE/ | unchanged | - | 1,266 | 3,182 | -% |
May 15, 2024 | Ally Bridge Group (NY) LLC | reduced | -0.66 | 797,127 | 2,023,800 | 1.12% |
May 15, 2024 | Northeast Financial Consultants Inc | unchanged | - | 76,000 | 191,000 | 0.01% |
May 15, 2024 | SPHERA FUNDS MANAGEMENT LTD. | added | - | 1,393,880 | 3,503,030 | 0.49% |
May 15, 2024 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 273 | 273 | -% |
May 15, 2024 | Royal Bank of Canada | unchanged | - | - | 1,000 | -% |
May 14, 2024 | Fiduciary Trust Co | unchanged | - | 15,206 | 38,215 | -% |
May 14, 2024 | Affinity Asset Advisors, LLC | unchanged | - | 202,128 | 507,980 | 0.06% |
May 13, 2024 | NATIONAL BANK OF CANADA /FI/ | unchanged | - | 147 | 599 | -% |
May 13, 2024 | BANK OF MONTREAL /CAN/ | new | - | 59,821 | 59,821 | -% |
Unveiling ProMIS Neurosciences, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to ProMIS Neurosciences, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
ProMIS Neurosciences, Inc. News
Balance Sheet | ||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 |
Assets | -73.9% | 3,548 | 13,619 | 17,876 | 1,498 | 4,428 | 6,925 | 5,382 | 10,189 | 13,968 | 17,747 | 1,086 |
Current Assets | -73.9% | 3,548 | 13,619 | 17,858 | 1,479 | 4,409 | 6,903 | 5,359 | 10,162 | - | 17,714 | 973 |
Cash Equivalents | -80.2% | 2,497 | 12,598 | 16,868 | 1,223 | 3,332 | 5,876 | 3,921 | 8,904 | 13,754 | 16,944 | 807 |
Net PPE | - | - | - | - | - | - | 321* | 788* | 3.00 | - | 5.00 | 78.00 |
Liabilities | -64.8% | 3,471 | 9,866 | 11,121 | 10,026 | 10,607 | 8,272 | 4,652 | 3,479 | 7,783 | 12,087 | 1,883 |
Current Liabilities | -71.7% | 2,646 | 9,350 | 9,851 | 8,739 | 8,706 | 6,413 | 3,099 | 1,874 | - | 929 | 1,883 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | 3,906 | - |
Shareholder's Equity | -97.9% | 77.00 | 3,753 | 6,755 | - | -6,179 | -1,347 | 730 | 6,710 | 3,738 | 5,660 | - |
Retained Earnings | -3.9% | -97,101 | -93,465 | -89,885 | -87,500 | -85,200 | -80,253 | -72,987 | -67,000 | - | -62,191 | -52,401 |
Additional Paid-In Capital | 0.0% | 97,549 | 97,590 | 97,012 | 79,368 | 79,234 | 79,101 | 73,988 | 73,879 | - | 68,039 | 51,655 |
Shares Outstanding | 0.4% | 18,961 | 18,885 | 18,525 | 8,579 | 8,579 | 8,579 | 7,196 | 7,196 | 7,196 | 7,196 | 4,829 |
Float | - | 29,700 | - | - | - | - | - | - | - | - | - | - |
Cashflow (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Cashflow From Operations | -173.8% | -10,291,447 | -3,758,238 | -2,376,462 | -2,147,322 | -2,561,654 | -4,553,628 | -4,635,698 | -4,477,789 | -3,366,768 | -4,046,680 | -3,030,266 | - | - |
Share Based Compensation | 1213.4% | 63,584 | 4,841 | - | 134,191 | 132,510 | 138,004 | 108,584 | 116,943 | 124,865 | 118,149 | 189,629 | 126,264 | - |
Cashflow From Investing | - | - | - | - | - | - | 43.00 | 24.00 | 9.00 | -2,057 | 95,805 | -3,559 | - | - |
Cashflow From Financing | 137.3% | 190,274 | -510,614 | - | - | - | - | - | - | - | 445 | 18,639,825 | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 2,123,778 | $ 3,510,252 |
General and administrative | 1,552,873 | 1,460,419 |
Total operating expenses | 3,676,651 | 4,970,671 |
Loss from operations | (3,676,651) | (4,970,671) |
Other income (expense): | ||
Change in fair value of financial instruments | (14,132) | (41,665) |
Interest expense | (76,775) | |
Other income | 132,470 | 52,905 |
Total other income (expense), net | 41,563 | 11,240 |
Net loss | (3,635,088) | (4,959,431) |
Other comprehensive loss | ||
Foreign currency translation adjustment | (4,354) | |
Comprehensive loss | $ (3,635,088) | $ (4,963,785) |
Net loss per share, basic | $ (0.19) | $ (0.58) |
Net loss per share, diluted | $ (0.19) | $ (0.58) |
Weighted-average shares outstanding of common shares, basic | 19,533,976 | 8,579,284 |
Weighted-average shares outstanding of common shares, diluted | 19,533,976 | 8,579,284 |
Condensed Consolidated Balance Sheets - USD ($) | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash | $ 2,496,973 | $ 12,598,146 |
Short-term investments | 32,358 | 32,358 |
Prepaid expenses and other current assets | 1,018,969 | 988,641 |
Total current assets | 3,548,300 | 13,619,145 |
Total assets | 3,548,300 | 13,619,145 |
Current liabilities: | ||
Accounts payable | 1,403,592 | 7,843,136 |
Accrued liabilities | 1,242,322 | 1,506,526 |
Total current liabilities | 2,645,914 | 9,349,662 |
Share-based compensation liability | 716,969 | 422,002 |
Warrant liability | 108,318 | 94,185 |
Total liabilities | 3,471,201 | 9,865,849 |
Commitments and contingencies | ||
Shareholders' equity (deficit): | ||
Series 2 Convertible Preferred Shares, no par value, unlimited shares authorized, 1,166,667 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||
Common shares, no par value, unlimited shares authorized, 18,961,116 and 18,885,254 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | ||
Additional paid-in capital | 97,549,317 | 97,590,426 |
Accumulated other comprehensive loss | (371,184) | (371,184) |
Accumulated deficit | (97,101,034) | (93,465,946) |
Total shareholders' equity (deficit) | 77,099 | 3,753,296 |
Total liabilities and shareholders' equity (deficit) | $ 3,548,300 | $ 13,619,145 |